ULTRAGENYX PHARMACEUTICAL INC. overview

Thinking about buying stock in Bank of America, Nio, Ultragenyx Pharmaceutical, Tilray, or Walmart? PR Newswire NEW YORK, Jan. 15, 2020 NEW YORK , Jan. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BAC, NIO, RARE, TLRY, and WMT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BAC:...

Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors PR Newswire PALO ALTO, Calif., Jan. 7, 2019 PALO ALTO, Calif. , Jan. 7, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray , MS, RAC to its Board of Directors. Ms. Murray is a pharmaceutical industry veteran...

REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors PR Newswire ROCKVILLE, Md., Oct. 22, 2018 ROCKVILLE, Md. , Oct. 22, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that Ultragenyx Pharmaceutical Inc. has exercised an option for...

NEW YORK, NY / ACCESSWIRE / February 20, 2018 / Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 20, 2018 at 5:00 PM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/22606 To receive updates for this company you can register by emailing [email protected] or by clicking get investment info from the company's profile. About...

WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders PR Newswire NEW YORK, Oct. 13, 2017 NEW YORK , Oct. 13, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dimension Therapeutics, Inc. ("DMTX" or the "Company") (NASDAQ: DMTX) in connection with the proposed acquisition of the Company by Ultragenyx Pharmaceutical Inc. ("RARE") (NASDAQ: RARE). On...

Dimension (DMTX) Alert: Johnson Fistel Investigates Proposed Sale of Dimension Therapeutics, Inc.; Are Shareholders Getting a Fair Price? PR Newswire SAN DIEGO, Oct. 3, 2017 SAN DIEGO , Oct. 3, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Dimension Therapeutics, Inc. (NASDAQ: DMTX) ("Dimension") breached their fiduciary duties in connection with the proposed sale of the Company to Ultragenyx Pharmaceutical...